Login to Your Account

Onyx Public Offering Will Beef Up Kyprolis Marketing Push

By Catherine Shaffer
Staff Writer

Thursday, January 17, 2013
Onyx Pharmaceuticals Inc.'s new multiple myeloma drug Kyprolis (carfilzomib) will get a $358.6 million boost following a new public offering of stock from the South San Francisco-based company.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription